This website is being migrated. In case you don't find the information you are looking for, the old website can be found here. Thank you for reporting any anomalies to communication@ill.eu.

News

colective.jpg
April 9, 2025 Supersymmetry shows up in condensed matter, not colliders
New findings based on neutron scattering experiments performed at the ILL and ISIS reveal supersymmetric behaviour in a quantum material, demonstrating that it can emerge naturally in condensed matter. This has promising practical implications for making stable qubits for quantum computing. The study, led by researchers at PSI, is published in Nature Communications.
219x288mm_plastic_water__cover_4.png
Feb. 12, 2025 Exotic observations at the ILL
In everyday life, we typically encounter water in one of three familiar states – solid, liquid or gas. But there are in fact many more phases, some of which – predicted to exist at high temperature and pressure – are so strange they’re referred to as exotic. State-of-the-art neutron spectrometers and sample environment infrastructures at the Institut Laue-Langevin (ILL) have enabled the first experimental observation of one of these exotic phases – plastic ice VII.
240522   Supercritical fluid dynamics_4x3.png
May 22, 2024 Unlocking the secrets of supercritical fluids
A study now published in Nature Communications brings remarkable insights into the enigmatic behaviour of supercritical fluids, a hybrid state of matter occupying a unique space between liquids and gases, and arising in domains ranging from the pharmaceutical industry to planetary science. The obtained results are at the limit of current experimental possibilities and could only be obtained in a high-flux neutron source such as the ILL.
radioisotopes.png
May 17, 2024 ILL is the chosen partner of Novartis to deliver a new cancer treatment drug
The Swiss company NOVARTIS announced at the Choose France Summit the desire to establish a partnership with the ILL, already a partner of other pharmaceutical companies for radioisotope production for cancer treatment and research. This is part of a plan to create a production unit intended to supply the French market with the first radioligand therapy (RLT) drug for the treatment of metastatic prostate cancer, an investment of close to 30 million euros in France.